<DOC>
	<DOCNO>NCT01624961</DOCNO>
	<brief_summary>The study design establish best dose safely infect healthy individual Plasmodium falciparum sporozoite ( PfSPZ ) via intravenous ( IV ) injection .</brief_summary>
	<brief_title>Controlled Human Malarial Infection Intravenous Injection Plasmodium Falciparum Sporozoites Non-Immune Adults</brief_title>
	<detailed_description>TÜCHMI-001 single center , open label , randomize control human pilot study optimize control human malaria infection ( CHMI ) administer PfSPZ Challenge . Volunteers inoculate PfSPZ Challenge . Controls receive PfSPZ Challenge ID administration . The remain volunteer receive PfSPZ Challenge IV administration . All volunteer recruit healthy adult age 18 45 year . Safety infectivity data collect regimens dose-levels . Volunteers clinical investigator blind group allocation , however laboratory investigator process blood film sample PCR analysis blind group allocation .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Malaria</mesh_term>
	<criteria>Healthy adult age 18 45 year Able willing ( Investigator 's opinion ) comply study requirement Willing allow investigator discuss volunteer 's medical history General Practitioner require Women : Must agree practice continuous effective contraception duration study ( method result low failure rate ; i.e . le 1 % per year ) Agreement refrain blood donation course study end involvement study accord local blood banking eligibility criterion Written inform consent undergo CHMI Reachable ( 24/7 ) mobile phone whole study period Willingness take curative antimalarial regimen Agreement stay overnight observation period intensive followup postchallenge require Answer question inform consent quiz correctly A body mass index &lt; 35 A haemoglobin concentration ≥12 g/dl woman ≥14 g/dl men History P. falciparum malaria History long term residence ( &gt; 5 year ) area know significant transmission P. falciparum Use systemic antibiotic know antimalarial activity within 30 day study enrolment ( e.g . trimethoprimsulfamethoxazole , doxycycline , tetracycline , clindamycin , erythromycin , fluoroquinolones , azithromycin ) Receipt investigational product 30 day precede enrolment , plan receipt study period Prior receipt investigational malaria vaccine HIV infection Any confirm suspected immunosuppressive immunodeficient state , asplenia , recurrent , severe infection chronic ( 14 day ) immunosuppressant medication within past 6 month ( inhaled topical steroid allow ) Use immunoglobulins blood product within 3 month prior enrolment Presence sickle cell anemia , sickle cell trait , thalassemia thalassemia trait Pregnancy , lactation intention become pregnant study A history allergic disease reaction likely exacerbate malaria Contraindications use firstline antimalarial medication : Atovaquone/Proguanil , Artemether/Lumefantrine , Chloroquine History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) History serious psychiatric condition may affect participation study Any serious chronic illness require hospital specialist supervision Suspected known current alcohol abuse define alcohol intake great 60g ( men ) 40g ( woman ) per day Suspected known injecting drug abuse 5 year precede enrolment Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV ) Falling moderate risk high category fatal nonfatal cardiovascular event within 5 year ( &gt; 10 % ) determine noninvasive criterion cardiac risk Abnormal electrocardiogram screening : pathologic Q wave significant STT wave change , leave ventricular hypertrophy , nonsinus rhythm except isolated premature atrial contraction , right leave bundle branch block , advance AV heart block ( secondary tertiary ) A QT/QTc interval &gt; 450 m Volunteers unable closely follow social , geographic psychological reason Any clinically significant abnormal find biochemistry haematology blood test , urinalysis clinical examination Any significant disease , disorder finding , opinion Investigator , may significantly increase risk volunteer participation study , affect ability volunteer participate study impair interpretation study data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Controlled human malaria infection ( CHMI )</keyword>
	<keyword>Malaria challenge</keyword>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>PfSPZ Challenge</keyword>
</DOC>